OncRef

Clinical Trial: NCT04722848

Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 3

Lead Sponsor:Gruppo Italiano Malattie EMatologiche dell'Adulto
Information Provided By:Gruppo Italiano Malattie EMatologiche dell'Adulto
Last Update Posted:2025-01-23

Study Overview

Brief Summary

This is a randomised, open-label, multicenter, phase III study for adult de novo Ph+ ALL patients based on the combination of Ponatinib with Blinatumomab. The control arm will be represented by a chemotherapeutic scheme combined with Imatinib for patients aged 18-65 and by Imatinib plus age-adjusted chemotherapy for elderly patients (>65 years old).

Patients will be randomized 2:1 to receive the experimental or control arm. If patients in the control arm do not achieve a CHR and/or MRD negativity, after the sixth consolidation cycle (week 20), a crossover to receive Blinatumomab is planned. Likewise, if patients in the control arm develop an ABL1 mutation at any time of treatment, they will switch to experimental arm. HLA typing will be performed immediately after diagnosis in both arms for patients aged up to 65 years.

After the 2 cycles of Blinatumomab in the experimental arm and after consolidation in the control arm, patients aged 18-65 will be stratified for transplant allocation.

Official Title

Newly Diagnosed Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL). Sequential Treatment With Ponatinib and the Bispecific Monoclonal Antibody Blinatumomab vs Chemotherapy and Imatinib

Conditions

Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive), ALL, Adult, Philadelphia-Positive ALL

Intervention / Treatment

  • Drug: Ponatinib + Blinatumomab
  • Drug: Chemotherapy + Imatinib

Other Study ID Numbers

  • ALL2820

Start Date (Actual)

2021-09-08

Primary Completion Date (Estimated)

2027-09

Study Completion Date (Estimated)

2027-09

Enrollment (Actual)

236

Study Type

Interventional

Phase

Phase 3